A systematic review of PuraStat for treating and preventing gastrointestinal bleeding
A systematic review on PuraStat’s safety and efficacy in treating and preventing bleeding in the gastrointestinal tract was recently conducted and presented as an abstract at the European Society of Gastrointestinal Endoscopy Congress 2023 in Dublin.
An independent systematic search was conducted in major electronic databases and in proceedings from major congresses. All eligible prospective and retrospective studies describing the endoscopic use of PuraStat (1) were considered. Primary outcomes evaluated rates of successful initial haemostasis, delayed bleeding, and rebleeding. Secondary outcomes were: adverse events, ease of use, and quantity of substance required.
A total of 3 randomised controlled trials and 14 observational studies were analysed. The overall success rate for haemostasis was 87.7 %, regardless of bleeding aetiology or associated treatments. Rebleeding rate average was 4.7 % (ranging from 0 - 16.2 %), and the overall delayed bleeding rate was 5.02 % (ranging from 0 - 15.91 %).
The volume of gel required varied based on purpose (haemostasis or prophylaxis) with the mean volume ranging from 0.43 to 3.7 ml. PuraStat ease of use was noted by most authors.
The authors conclude that their review suggests a high efficiency and good safety profile of PuraStat in gastrointestinal endoscopy.
Click here to read the full abstract.
(1) - PuraStat IFU-007 Rev-2.